Form 4: Shattuck Labs CFO Exercises Warrants for 64,027 Shares

Shattuck Labs CFO Andrew R. Neill exercised warrants to acquire 64,027 shares of common stock at a price of $1.0846 per share.

Summary

• CFO Andrew R. Neill exercised warrants to acquire 64,027 shares of Shattuck Labs common stock.
• The transaction occurred on May 12, 2026, at an exercise price of $1.0846 per share.
• Following this transaction, the reporting person's total beneficial ownership of common stock increased to 292,251 shares.
• The warrants were originally acquired as part of a private placement securities purchase agreement dated August 4, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive event, as it reflects internal confidence from the CFO, though it is a routine administrative filing regarding existing equity holdings.

Positives

• Insider confidence is demonstrated by the CFO's decision to exercise warrants and increase his equity stake in the company.
• The transaction reflects the conversion of previously held derivative securities into direct common stock ownership.

Negatives

• The exercise price of $1.0846 suggests a relatively low valuation for the company's equity at the time of the original warrant issuance.

Risks

• The exercise of warrants is tied to the clinical development of SL-325, specifically the announcement of Phase 1 trial data and Phase 2 trial design.
• Future share price performance remains dependent on the successful clinical progression of the company's pipeline.

Future Outlook

The exercise of warrants is contingent upon the public announcement of Phase 1 clinical trial data for SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial.

Management Comments

• The filing does not contain narrative management commentary beyond the required disclosure of the transaction.

Industry Context

StockSavvy.ai notes that insider warrant exercises in the biotech sector are common following private placements, often signaling management's alignment with long-term clinical milestones rather than immediate market sentiment.

Comparison to Industry Standards

• The transaction is consistent with standard executive compensation and equity participation structures in clinical-stage biotechnology firms.
• The use of warrants as part of a private placement is a common mechanism for biotech companies to raise capital while providing upside potential to investors and insiders.

Related Party Transactions

• The reporting person participated in a private placement of securities previously disclosed in the August 2025 purchase agreement.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive signal of management's commitment to the company's long-term clinical success.

Next Steps

• Public announcement of Phase 1 clinical trial data for SL-325.
• Public disclosure of the design for the planned Phase 2 clinical trial.

Key Dates

Keywords

Shattuck Labs, STTK, Insider Trading, Form 4, Biotech, Warrant Exercise, CFO